CAJ | 학술논문

目的：探讨晚期非小细胞肺癌患者经吉非替尼治疗前后血清癌胚抗原（CEA）水平的变化及意义。方法40例Ⅲ～Ⅳ期晚期非小细胞肺癌患者为研究对象，入院后给予吉非替尼治疗，同时给予患者常规局部放疗，直到患者肿瘤进展或难以耐受时停药。所有患者治疗前、后均行血清 CEA 检测，根据治疗前的 CEA 水平将40例患者分为高 CEA 组和低 CEA 组，随访至2013年12月，观察2组患者不良反应发生情况及无进展生存时间（PFS）。治疗结束后，根据评价结果分为控制组和非控制组，观察2组血清 CEA 水平的变化。结果治疗前，控制组和非控制组血清 CEA 水平无显著差异（P ＞0．05）；治疗后，2组血清 CEA 水平较治疗前明显降低（P ＜0．01）。控制组治疗后血清 CEA 水平明显低于非控制组（P ＜0．01）。高 CEA 组不良反应发生率均高于低 CEA 组，但2组不良反应发生率无统计学差异（P ＞0．05）。CEA 高水平患者9个月、12个月的生存率明显高于 CEA 低水平的患者（P ＜0．05）。结论血清 CEA 水平可以作为评估吉非替尼治疗晚期非小细胞肺癌的预后生化指标。
목적：탐토만기비소세포폐암환자경길비체니치료전후혈청암배항원（CEA）수평적변화급의의。방법40례Ⅲ～Ⅳ기만기비소세포폐암환자위연구대상，입원후급여길비체니치료，동시급여환자상규국부방료，직도환자종류진전혹난이내수시정약。소유환자치료전、후균행혈청 CEA 검측，근거치료전적 CEA 수평장40례환자분위고 CEA 조화저 CEA 조，수방지2013년12월，관찰2조환자불량반응발생정황급무진전생존시간（PFS）。치료결속후，근거평개결과분위공제조화비공제조，관찰2조혈청 CEA 수평적변화。결과치료전，공제조화비공제조혈청 CEA 수평무현저차이（P ＞0．05）；치료후，2조혈청 CEA 수평교치료전명현강저（P ＜0．01）。공제조치료후혈청 CEA 수평명현저우비공제조（P ＜0．01）。고 CEA 조불량반응발생솔균고우저 CEA 조，단2조불량반응발생솔무통계학차이（P ＞0．05）。CEA 고수평환자9개월、12개월적생존솔명현고우 CEA 저수평적환자（P ＜0．05）。결론혈청 CEA 수평가이작위평고길비체니치료만기비소세포폐암적예후생화지표。
Objective To discuss significance of carcinoembryonic antigen level changes be-fore and after the treatment of gefinitib in patients with non-small cell lung cancer(NSCLC). Methods 40 patients with advanced NSCLC in Ⅲ~Ⅳ period were enrolled and given routine local chemotherapy and gEfitinib,and the therapy was which until the patients were intolerant to it.All the patients were given carcinoembryonic antigen (CEA)test before and after treatment and were divided into high CEA group and low CEA group according to CEA level before treatment.Follow-up lasted until December 2013,adverse reactions and PFS in 2 groups were observed.Results Before treatment,the difference was not significant in CEA levels in control group and uncontrolled group (P >0.05).After treatment,CEA levels in 2 groups were obviously lower than the treat-ment before (P <0.01)and CEA level in control group was obviously lower than that in the uncon-trolled group(P <0.01).Occurrence rate of adverse reactions in high CEA group was higher than low CEA group but the difference were not significant (P >0.05).Survival rates of 9 and 12 months in high CEA group were markedly higher than that in thee low CEA group (P <0.05). Conclusion CEA level can be considered as a biochemical index of assessing prognosis of gefitinib in treatment of advanced NSCLC.